Lilly Reports Results of Tirzepatide in P-lll SURPASS-2 Trial for Type-2 Diabetes

 Lilly Reports Results of Tirzepatide in P-lll SURPASS-2 Trial for Type-2 Diabetes

Lilly Reports Results of Tirzepatide in P-lll SURPASS-2 Trial for Type-2 Diabetes

Shots:

  • The P-III SURPASS-2 trial involves assessing Tirzepatide (5/10/15mg) vs Semaglutide (1mg) in 1,879 patients in a ratio (1:1:1:1) with T2D inadequately controlled with ≥1500 mg/day metformin alone for 40wks.
  • Results: A1C reduction: (-2.09% /-2.37%/-2.46% vs- 1.86%); Weight reduction: (-7.8/-10.3/-12.4kg vs -6.2 kg); patients achieving A1C <7% (5.5%/88.9%/ 92.2% vs 81.1%); patients achieving A1C <5.7% (29.3% /44.7%/50.9% vs 19.7%) respectively
  • The highest & lowest doses of therapy (15 & 5mg) led to an A1C reduction of 2.46 % & 2.09% with a reduction in body weight by 12.4 kg (13.1 %) & 7.8 kg (8.5%). Thus, all three doses of Tirzepatide showed a reduction in A1C and body weight

Click here ­to­ read full press release/ article | Ref: Lilly | Image: BioSpace

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post